Workflow
华丽家族:拟不超过3亿元增资上海海和药物研究开发股份有限公司

Group 1 - The company, Huayi Family, plans to invest no more than 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement financing [1] - The subscription price for the new shares is set at 4.75 yuan per share, with a maximum of 63,157,895 new shares to be acquired [1] - After the completion of this capital increase, the company's shareholding in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1] Group 2 - This capital increase is viewed as a strategic financial investment by the company, reflecting confidence in the long-term development potential of innovative drugs [1] - The investment aims to ensure stable operations of the main business while obtaining reasonable financial returns and exploring opportunities in emerging industries [1]